| Reporting Period | Filing Date | Average Time to Pay (days) | Paid within 30 days | Paid 31-60 days | Paid after 60 days | Not Paid within Terms |
|---|---|---|---|---|---|---|
| 01 Jul 2025 - 31 Dec 2025 | 30 Jan 2026 | 29 | 69% | 22% | 9% | 52% |
| 01 Jan 2025 - 30 Jun 2025 | 06 Aug 2025 | 42 | 65% | 16% | 19% | 59% |
| 01 Jul 2024 - 31 Dec 2024 | 19 Feb 2025 | 63 | 62% | 16% | 22% | 63% |
| 01 Jan 2024 - 30 Jun 2024 | 31 Jul 2024 | 34 | 22% | 63% | 15% | 9% |
| 01 Jul 2023 - 31 Dec 2023 | 31 Jan 2024 | 34 | 57% | 30% | 13% | 14% |
| 01 Jan 2023 - 30 Jun 2023 | 20 Jul 2023 | 30 | 73% | 16% | 11% | 4% |
| 01 Jul 2022 - 31 Dec 2022 | 27 Jan 2023 | 34 | 61% | 24% | 15% | 37% |
| 01 Jan 2022 - 30 Jun 2022 | 22 Jul 2022 | 31 | 76% | 21% | 3% | 30% |
| 01 Jul 2021 - 31 Dec 2021 | 30 Jan 2022 | 26 | 69% | 23% | 8% | 36% |
| 01 Jan 2021 - 30 Jun 2021 | 29 Jul 2021 | 30 | 56% | 39% | 5% | 12% |
| 01 Jul 2020 - 31 Dec 2020 | 29 Jan 2021 | 31 | 48% | 47% | 5% | 55% |
| 01 Jan 2020 - 30 Jun 2020 | 30 Jul 2020 | 27 | 63% | 33% | 4% | 44% |
| 01 Jul 2019 - 31 Dec 2019 | 28 Jan 2020 | 18 | 92% | 7% | 1% | 11% |
| 01 Jan 2019 - 30 Jun 2019 | 29 Jul 2019 | 23 | 77% | 20% | 3% | 24% |
| 01 Jul 2018 - 31 Dec 2018 | 29 Jan 2019 | 18 | 85% | 14% | 1% | 15% |
| 01 Jan 2018 - 30 Jun 2018 | 30 Jul 2018 | 26 | 73% | 21% | 6% | 27% |
This information is as reported by the business, and responses are in their own words.
Standard payment terms
The default position is 90 days, however there may be changes to this default position on a case-by-case basis pending agreement with suppliers. On a case-by-case basis, payment terms to suppliers may be immediate payment or payment on terms within 7, 14, 30 or 60 days.
Were there any changes to the standard payment terms in the reporting period?
No information available
Any other information about payment terms
No additional information
Maximum contractual payment period agreed
90
If a supplier has a query or dispute relating to a payment they believe is owed to them by Napp Pharmaceutical Holdings Ltd (NPH), the supplier is to email the below details to napp.apqueries@mundipharma.com a. Full supplier name, address; b. The name of your NPH point of contact; c. Invoice number for the payment you are querying; d. Full details of your complaint; e. Upon receipt of all of the above details, NPH commits to acknowledge receipt of the suppliers email within five working days, and may request further information to be able to respond in full. NPH will investigate the supplier query using the details provided and speak with relevant members of NPH’s business, including members of NPH’s legal department if necessary, and respond in full within 14 days of the date of NPH’s acknowledgement to the supplier.
Has this business signed up to a code of conduct or standards on payment practices?
For example, signatories to The Prompt Payment Code must commit to paying 95% of their invoices within 60 days.
❌
Does this business offer e-invoicing in relation to qualifying contracts?
This is where suppliers can electronically submit and track invoices. It's not just allowing suppliers to email them an invoice.
❌
Does this business offer supply chain finance?
This is where a supplier who has submitted an invoice can be paid by a third-party finance provider earlier than the agreed payment date. The business would then pay the finance provider the invoiced sum.
❌
Under its payment practices and policies, can this business deduct sums from payments under qualifying contracts as a charge for remaining on a supplier list?
❌
During the reporting period, did the business deduct sums from payments as a charge for remaining on a supplier list?
No information available
NAPP PHARMACEUTICAL HOLDINGS LIMITED is a UK-based pharmaceutical company that specializes in the research, development, and distribution of innovative medicines. The company is committed to sustainability and has implemented various initiatives to reduce its environmental impact and promote social responsibility.
Some of NAPP's sustainability efforts include reducing carbon emissions, managing waste and water usage, and promoting ethical practices within its supply chain. The company also supports various charitable causes and encourages its employees to volunteer in their local communities.
NAPP offers a wide range of products and services, including prescription medicines, over-the-counter drugs, and medical devices. Their portfolio covers a variety of therapeutic areas, such as pain management, respiratory diseases, and mental health.
The key people at NAPP PHARMACEUTICAL HOLDINGS LIMITED include the CEO, Dr. Paul Bowie, who has over 30 years of experience in the pharmaceutical industry. The company's registered office address is located at Cambridge Science Park, Milton Road, Cambridge, CB4 0GW, United Kingdom.
To learn more about NAPP and its products and services, you can visit their website at https://www.napp.co.uk/. The website also provides contact information for general inquiries and medical information requests. NAPP PHARMACEUTICAL HOLDINGS LIMITED is dedicated to improving the lives of patients through sustainable and ethical practices, making them a trusted and responsible player in the pharmaceutical industry.
Proud of your payment record? Show your live score on your own site:
<iframe src="https://paymentcheck.co.uk/badge/03486244" width="240" height="72" style="border:0" title="PaymentCheck Score" loading="lazy"></iframe>